An investor’s perspective on bio and tech
Increasingly, the life sciences world is characterised by the collision of the worlds of technology and biology. This manifests itself in many ways, from AI innovations in drug discovery and development to digital health, therapeutics, and biomarkers.
In today’s episode of the pharmaphorum podcast, host Jonah Comstock sits down for a wide-ranging conversation with Artem Trotsyuk, an investor with LongeVC, his fund focused on therapeutics, diagnostics, and life sciences infrastructure plays.
They talk about AI drug discovery and why it’s important for companies to pursue the whole value chain, rather than laser-focusing on target generation. Trotsyuk shares what he looks for in a biotech investment.
They also get into the world of cell and gene therapy, including how gene therapy could eventually be more than just disease treatment. And they discuss digital health and digital therapeutics and the challenges of bringing real, systemic change to healthcare.
It’s almost the holidays, so sit down, relax, and enjoy a freewheeling discourse about health and tech.
You can listen to episode 108 of the pharmaphorum podcast in the player below, download the episode to your computer or find it - and subscribe to the rest of the series - in iTunes, Spotify, acast, Stitcher, and Podbean.
